enalkiren

Subscribe to Selected New Research on enalkiren

12 relevant articles (1 outcomes, 5 trials/studies) found for this Bio-Agent

Also Known As:

(N-(3-amino-3-methyl-1-oxobutyl)-4-methoxy-L-phenylalanyl)-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-L-histidinamide; A 64662; A-64662; Abbott 64662; L-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1S-(1R*,2S*,3R*))-

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Related Diseases

1.	Hypertension (High Blood Pressure) 05/01/1995 - "We pursued this discrepancy in the current study of 18 healthy men and 9 men with essential hypertension, who each received one or more doses of enalkiren while on a fixed sodium diet" 01/01/1990 - "The results of clinical trials with enalkiren are encouraging, and suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension." 12/01/1990 - "The effect of the direct renin inhibitor enalkiren (Abbott Laboratories) was examined in 8 healthy patients with essential hypertension" 06/01/1990 - "The prolonged reduction in blood pressure with enalkiren without evidence of tachyphylaxis after 1 week of treatment suggests that renin inhibitors may emerge as useful therapeutic agents for the treatment of hypertension." 06/01/1990 - "Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension." Get all the results and reference details, order at left...
2.	Heart Failure 05/01/1993 - "This study describes the relationship between the measured effects (the acute effects on systemic hemodynamics and cardiac function) and plasma drug levels using a combined pharmacokinetic-pharmacodynamic model after i.v. infusion dosing of enalkiren (A-64662) in patients with congestive heart failure" 01/01/1991 - "Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure." Get all the results and reference details, order at left...
3.	Hypotension (Low Blood Pressure) 03/01/1989 - "This study indicates that continuous infusion of A-64662 results in a sustained hypotension in sodium-depleted monkeys" Get all the results and reference details, order at left...
4.	Ganglion Cysts (Ganglion) 11/01/1999 - "The intravenous infusion of recombinant human renin (2.4 microg x kg(-1) x min(-1)) in the ganglion-blocked, nephrectomized rat produced a mean blood pressor response of 47+/-3 mm Hg (1 mm Hg = 133.3 Pa), which was reduced by captopril, enalkiren, and losartan in a dose-dependent manner following oral administration, with ED50 values of 0.3+/-0.1, 2.5+/-0.9, and 5.2+/-1.6 mg/kg, respectively" Get all the results and reference details, order at left...
5.	Oliguria 02/01/1994 - "Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria." 02/01/1994 - "1. The haemodynamic and hormonal responses of four patients with acute post-surgical oliguria (urine output < 0.5 mL/kg per h) were measured in response to the renin inhibitor enalkiren" Get all the results and reference details, order at left...
5 Diseases and 12 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Renin
2.	Epoprostenol (Prostacyclin)
3.	Sodium
4.	Losartan (Cozaar)
5.	Captopril (Capoten)
6.	Angiotensin II
7.	Aldosterone
7 Drugs and Important Bio-Agents and 11 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>